Article
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.
Pharmacogenetics and genomics - 1 Jun 2018
Ingle James N, Kalari Krishna R, Wickerham Donald Lawrence, von Minckwitz Gunter, Fasching Peter A, Furukawa Yoichi, Mushiroda Taisei, Goetz Matthew P, Barman Poulami, Carlson Erin E, Rastogi Priya, Costantino Joseph P, Cairns Junmei, Paik Soonmyung, Bear Harry D, Kubo Michiaki, Wang Liewei, Wolmark Norman, Weinshilboum Richard M
Abstract excerpt
Neoadjuvant chemotherapy (NAC) for breast cancer is widely utilized, and we performed genome-wide association studies (GWAS) to determine whether germ-line genetic variability was associated with benefit in terms of pathological complete response (pCR), disease-free survival, and overall survival in patients entered on the NSABP B-40 NAC trial, wherein patients were randomized to receive, or not, bevacizumab in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.